Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$3.93M$3.93M+400.3% vs Q3 2016 Net Income-$7.06M-$7.06MN/M vs Q3 2016 EPS Diluted-$0.16-$0.16N/M vs Q3 2016 Operating Income-$5,184,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$34,910,000N/M Margins · derivedOperating margin-132.0%+655.0 pt vs Q3 2016
Net margin-179.8%+609.6 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 13, 2017 · 44 d after period end